# Antibiotic Treatment Guidelines for Urinary Tract Infections in Children (60 Days Through 17 Years)

This guideline provides guidance for most children 60 days through 17 years of age. Management of urinary tract infections (UTI) in infants <60 days, pregnant patients, or in patients with recurrent UTIs is beyond the scope of these guidelines. Please refer to the Febrile Infant Guideline for infants <60 days.

<table>
<thead>
<tr>
<th>Setting</th>
<th>Empiric Therapy</th>
<th>Duration/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outpatient</strong></td>
<td><strong>1&lt;sup&gt;st&lt;/sup&gt; line for adolescents (10 years or older) with cystitis only:</strong></td>
<td>Duration:</td>
</tr>
<tr>
<td></td>
<td>Nitrofurantoin&lt;sup&gt;*&lt;/sup&gt; as MacroBID (or generic equivalent) 100 mg/DOSE PO BID (flat dose)</td>
<td>Nitrofurantoin: 5 days</td>
</tr>
<tr>
<td></td>
<td><strong>1&lt;sup&gt;st&lt;/sup&gt; line for infants and children OR if pyelonephritis is suspected; alternative for nitrofurantoin allergy:</strong></td>
<td>Other agents:</td>
</tr>
<tr>
<td></td>
<td>Cephalexin&lt;sup&gt;*&lt;/sup&gt; 25 mg/kg/DOSE PO TID (max: 1 g/DOSE)</td>
<td>&lt;6 months:</td>
</tr>
<tr>
<td></td>
<td>Alternative for low/medium&lt;sup&gt;1&lt;/sup&gt;-risk allergy to cephalexin&lt;sup&gt;2&lt;/sup&gt;, OR high-risk allergy&lt;sup&gt;/&lt;/sup&gt;contraindication&lt;sup&gt;4&lt;/sup&gt; to beta-lactam:</td>
<td>10 days</td>
</tr>
<tr>
<td></td>
<td>TMP-SMX&lt;sup&gt;5&lt;/sup&gt;: 5 mg TMP/kg/DOSE PO BID (max: 160 mg/DOSE)</td>
<td>≥6 months:</td>
</tr>
<tr>
<td></td>
<td>Alternative to TMP-SMX for sulfa allergy:</td>
<td>7 days</td>
</tr>
<tr>
<td></td>
<td>Ciprofloxacin&lt;sup&gt;*&lt;/sup&gt; 10 mg/kg/DOSE PO BID (max: 500 mg/DOSE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Duration:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nitrofurantoin: 5 days</td>
<td></td>
</tr>
<tr>
<td><strong>Inpatient, uncomplicated</strong></td>
<td><strong>1&lt;sup&gt;st&lt;/sup&gt; line therapy:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ampicillin&lt;sup&gt;*&lt;/sup&gt; 50 mg/kg/DOSE IV q6h (max: 1 g/DOSE)</td>
<td>Duration ([IV + PO])</td>
</tr>
<tr>
<td></td>
<td>+ Gentamicin&lt;sup&gt;*&lt;/sup&gt; 7.5 mg/kg/DOSE IV q24h (max initial: 300 mg/DOSE)</td>
<td>&lt;6 months:</td>
</tr>
<tr>
<td></td>
<td>Alternative for low/medium&lt;sup&gt;1&lt;/sup&gt;-risk penicillin allergy, OR high-risk allergy&lt;sup&gt;/&lt;/sup&gt;contraindication&lt;sup&gt;4&lt;/sup&gt; to beta-lactam:</td>
<td>10 days</td>
</tr>
<tr>
<td></td>
<td>Gentamicin&lt;sup&gt;*&lt;/sup&gt; 7.5 mg/kg/DOSE IV q24h (max initial: 300 mg/DOSE)</td>
<td>≥6 months:</td>
</tr>
<tr>
<td></td>
<td><strong>Comments</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consider prior cultures and recent antibiotic use when selecting empiric therapy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tailor therapy to culture results.</td>
<td></td>
</tr>
<tr>
<td><strong>Inpatient, uncomplicated</strong></td>
<td><strong>Tailor therapy to culture results and transition to oral therapy following clinical improvement, as evidenced by improving fever curve and ability to tolerate PO. See Outpatient recommendations for preferred regimens.</strong></td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup>Low-risk allergy

<sup>2</sup>Medium-risk allergy

<sup>3</sup>High-risk allergy

<sup>4</sup>Contraindication

<sup>5</sup>5 mg TMP/kg/DOSE PO BID (max: 160 mg/DOSE)
<table>
<thead>
<tr>
<th>Setting</th>
<th>Empiric Therapy</th>
<th>Duration/Comments</th>
</tr>
</thead>
</table>
| **Inpatient, complicated by severe sepsis, bacteremia, or perinephric/renal abscess** | **Community-acquired, healthy child:**  
  **Ceftriaxone** 100 mg/kg once, then 50 mg/kg/DOSE IV q12h (max: 2 g/DOSE)  
  + **Vancomycin IV**  
  **Presence of central venous catheter or tracheostomy, greater than 72 hours of hospitalization in past 90 days, or immunocompromised:**  
  **Cefepime**  50 mg/kg/DOSE IV q8h (max: 2 g/DOSE)  
  + **Vancomycin IV**  
  **Alternative for low/medium-risk allergy to cephalosporins, OR high-risk allergy/contraindication to beta-lactam:**  
  **Aztreonam** 50 mg/kg/DOSE IV q8h (max: 2 g/DOSE)  
  + **Vancomycin IV** | **Duration (IV + PO)**  
  <6 months:  
  10 days, unless delayed improvement  
  ≥6 months:  
  7 days, unless delayed improvement  
  Patients with bacteremia or abscess may require longer therapy; Infectious Diseases consult recommended.  
  **Comments**  
  Consider prior cultures and recent antibiotic use when selecting empiric therapy.  
  Consider Urology consult in patients with GU abnormalities.  
  Tailor therapy to culture results and consider transition to oral therapy following clinical improvement, as evidenced by improving fever curve and ability to tolerate PO. See Outpatient recommendations for preferred regimens. |

**Emergency Department**  
**Anticipated discharge to home:**  
- Prescribe antibiotics per Outpatient recommendations  
**Not tolerating PO with negative sepsis screen:**  
- Begin empiric therapy per Inpatient recommendations (select uncomplicated or renal dysfunction/transplant as appropriate)  
- Transition to Outpatient empiric therapy if able to discharge  
**Positive sepsis screen and/or known bacteremia/abscess:**  
- Begin empiric therapy per Complicated Inpatient recommendations  
  - Initial ED **vancomycin** dose: 15 mg/kg once for all patients (max: 1.5 g/DOSE)  
  - If signs/symptoms of sepsis resolve and low concern for abscess or bacteremia, transition to Uncomplicated Inpatient recommendations |
Footnotes:

* Renal adjustment may be necessary. See Pediatric Renal Dosing Guidelines.

1. Low-risk allergies include: pruritus without rash, remote (>10 years) unknown reaction, patient denies allergy but is on record, mild rash with no other symptoms (mild rash: non-urticarial rash that resolves without medical intervention). Medium-risk allergies include: urticaria/hives with no other symptoms, severe rash with no other symptoms (severe rash: requires medical intervention [corticosteroids, anti-histamines] and/or ER visit or hospitalization). See β-lactam allergy evaluation and empiric guidance for further information.

2. This also includes allergy to cephalosporins with a similar side-chain to cephalaxin, which includes cefaclor, cefadroxil, or cefprozil. See β-lactam allergy evaluation and empiric guidance for further information.

3. High-risk allergies include: respiratory symptoms (chest tightness, bronchospasm, wheezing, cough), angioedema (swelling, throat tightness), cardiovascular symptoms (hypotension, dizzy/lightheadedness, syncope/passing out, arrhythmia), anaphylaxis. If a patient has a high-risk allergy to penicillins, cephalosporins, or carbapenems, the only beta-lactam antibiotic that can be safely used without Allergy consult is aztreonam (if the allergy is to ceftazidime or aztreonam, aztreonam should be avoided as well). See β-lactam allergy evaluation and empiric guidance for further information.

4. Previous reactions that are contraindications to further beta-lactam use (except aztreonam, which can be used unless the reaction was to ceftazidime or aztreonam) unless approved by Allergy: organ damage (kidney, liver), drug-induced immune-mediated anemia/thrombocytopenia/leukopenia, rash with mucosal lesions (Stevens Johnson Syndrome/Toxic Epidermal Necrosis), rash with pustules (acute generalized exanthematous pustulosis), rash with eosinophils and organ injury (DRESS – drug rash eosinophilia and systemic symptoms), rash with joint pain, fever, and myalgia (Serum Sickness). See β-lactam allergy evaluation and empiric guidance for further information.

5. TMP-SMX = trimethoprim-sulfamethoxazole

References:


Authors:

Shannon Taut, MD; House Officer, Pediatrics
Wendi-Jo Wendt, MD; House Officer, Pediatrics
Nicholas Dillman, PharmD; Pediatric Infectious Diseases and Antimicrobial Stewardship
Kristin Klein, PharmD; Pediatric Infectious Diseases and Antimicrobial Stewardship
Alison Tribble, MD; Pediatric Infectious Diseases and Antimicrobial Stewardship

Consultants:

Elizabeth Gorski, PharmD; Pediatric Clinical Pharmacy Specialist
Kimberly Monroe, MD; Pediatric Hospital Medicine
Nico Sroufe, MD; Pediatric Emergency Medicine
Terri Stillwell, MD, MPH; Pediatric Infectious Diseases
Julian Wan, MD; Pediatric Urology
Larysa Wickman, MD; Pediatric Nephrology

<table>
<thead>
<tr>
<th>Antimicrobial Subcommittee Approval:</th>
<th>06/2020</th>
<th>Originated: Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>P&amp;T Approval:</td>
<td>07/2017, 07/2020</td>
<td>Last Revised: 03/2021</td>
</tr>
</tbody>
</table>

Revision History:

09/2020: Updated allergy guidance, updated aztreonam dosing.
03/2021: Updating vancomycin hyperlinks.

C&W Operations Subcommittee: 07/2017
C&W Executive Committee: 08/2017

The recommendations in this guide are meant to serve as treatment guidelines for use at Michigan Medicine facilities. If you are an individual experiencing a medical emergency, call 911 immediately. These guidelines should not replace a provider’s professional medical advice based on clinical judgment, or be used in lieu of an Infectious Diseases consultation when necessary. As a result of ongoing research, practice guidelines may from time to time change. The authors of these guidelines have made all attempts to ensure the accuracy based on current information, however, due to ongoing research, users of these guidelines are strongly encouraged to confirm the information contained within them through an independent source.

If obtained from a source other than med.umich.edu/asp, please visit the webpage for the most up-to-date document.